x

Search for a clinical trial

* (*) mandatory field

231 Result(s)

Sort by

Recruiting trial = Recruiting trial
; Ongoing trial = Ongoing trial
; Funded by an IRDiRC member =

National clinical trial(s)

AUSTRIA

OBERÖSTERREICH
LINZ

AUSTRIA

OBERÖSTERREICH
LINZ

Recruiting trial
Ongoing trial
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) - AT
Ordensklinikum Linz - Elisabethinen
Hämatologie mit Stammzelltransplantation, Hämostaseologie und medizinische Onkologie

AUSTRIA

SALZBURG
SALZBURG

AUSTRIA

TIROL
INNSBRUCK

GERMANY

Baden-Württemberg
HEIDELBERG

Recruiting trial
Ongoing trial
BLAST: A double- blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 addition to consolidation therapy in AML patients - DE
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

GERMANY

Hessen
FRANKFURT AM MAIN

GERMANY

Nordrhein-Westfalen
DÜSSELDORF

GERMANY

Nordrhein-Westfalen
ESSEN

Recruiting trial
Ongoing trial
AML-BFM 2012: Clinical trial for the treatment of acute myeloid leukemia in children and adolescents
Universitätsklinikum Essen
Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie

GERMANY

Nordrhein-Westfalen
LEVERKUSEN

CLAVELA: A randomised phase III study of Elacytarabine versus investigator's choice in patients with late stage Acute Myeloid Leukaemia - DE - Completed
Klinikum Leverkusen
Medizinische Klinik 3 - Onkologie, Hämatologie, Palliativmedizin, Spezielle Schmerztherapie

GERMANY

Sachsen
DRESDEN

Recruiting trial
Ongoing trial
TUD-BRIDGE-046: Clofarabine salvage therapy in patients with relapsed or refractory Acute Myeloid Leukemia (Phase II Study)
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANY

Sachsen
DRESDEN

Recruiting trial
Ongoing trial
HINKL: Randomised controlled phase-2 trial to determine the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANY

Sachsen
DRESDEN

Recruiting trial
Ongoing trial
DELTA: A randomized placebo-controlled phase 2 study of decitabine/azacitidine with or without eltrombopag in AML patients = / > 65 years of age not eligible for intensive chemotherapy - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANY

Sachsen
DRESDEN

Recruiting trial
Ongoing trial
ETAL3-ASAP: Evaluation of the Impact of Remission Induction Chemotherapy Prior to Allogeneic Stem Cell Transplantation in Relapsed and Poor-response Patients with AML (Phase III) - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

ITALY

EMILIA ROMAGNA
BOLOGNA

NETHERLANDS

Gelderland
NIJMEGEN

Recruiting trial
Ongoing trial
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1
Radboudumc - Radboud universitair medisch centrum
Afdeling Hematologie

POLAND

Wroclaw
WROCLAW

CLAVELA: A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia - PL
Uniwersytet Medyczny im. Piastow Slaskich - Wroclaw Medical University
Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku

SPAIN

Comunidad Valenciana
VALENCIA

SPAIN

Comunidad Valenciana
VALENCIA

SPAIN

Navarra
PAMPLONA

CLAVELA: A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia - ES (completed)
Complejo Hospitalario de Navarra - Hospital Virgen del Camino
Servicio de Hematología y Hemoterapia

UNITED KINGDOM

Nottinghamshire
NOTTINGHAM

UNITED KINGDOM

South Glamorgan
CARDIFF

AML 14: A Randomised Trial for Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome Aged 60 or over (phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

GERMANY

Sachsen
DRESDEN

Recruiting trial
Ongoing trial
RELAZA2 (TUD-RELA02-048): Treatment of patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) with an impending hematological relapse with Azacitidin (Phase II)
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

DENMARK

Jylland
AARHUS

NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia (Phase III)
Aarhus Universitetshospital - Skejby
Department of Pediatrics

FRANCE

AUVERGNE-RHONE-ALPES
LYON

CLARA-DNX : A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML
CHU de Lyon HCL - GH Est-Institut d'hématologie et d'oncologie pédiatrique IHOP
Service d'immuno-hématologie pédiatrique et de transplantation de moelle osseuse

FRANCE

ILE-DE-FRANCE
BOBIGNY

Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) (Phase III)
CHU Paris Seine-Saint-Denis - Hôpital Avicenne
Service d'hématologie clinique

FRANCE

ILE-DE-FRANCE
PARIS

5-Azacitidine, Valproic Acid and ATRA in AML and High Risk MDS (Phase II) - Terminated -
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Maladies du sang

FRANCE

OCCITANIE
MONTPELLIER

FRANCE

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Acute Myeloid Leukemia - Terminated -
CLCC Institut Paoli Calmettes
Unité d'Evaluation Thérapeutique en Onco-Hématologie (ETHO)

FRANCE

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

FRANCE

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

GERMANY

Baden-Württemberg
FREIBURG

GERMANY

Baden-Württemberg
FREIBURG

Phase III study of low-dose intravenous decitabine in patients aged > 60 years with acute myeloid leukemia who are not eligible for standard induction chemotherapy - DE
Universitätsklinikum Freiburg
Klinik für Innere Medizin I - Hämatologie, Onkologie und Stammzelltransplantation

GERMANY

Baden-Württemberg
HEIDELBERG

GERMANY

Baden-Württemberg
HEIDELBERG

Phase II open-label, AC220 monotherapy efficacy (ACE) study in patients with Acute Myeloid Leukemia (AML) with FLT3-ITD activating mutations - DE
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

GERMANY

Baden-Württemberg
TÜBINGEN

Recruiting trial
Ongoing trial
CD3/CD19 Haplo (E410/2007): Multicenter phase II study of Haploidentical Hematopoietic Cell Transplantation with CD3/CD19 depleted Grafts after a reduced intensity conditioning regimen for adult Patients with Acute Leukemia
Department für Innere Medizin - Medizinische Universitätsklinik Tübingen
Innere Medizin II - Onkologie, Hämatologie, Klinische Immunologie, Rheumatologie und Pulmologie

GERMANY

Berlin
BERLIN

WT1 Vaccination: Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in AML - DE
Charité - Universitätsmedizin Berlin (CCM)
Charité Comprehensive Cancer Center (CCCC)

GERMANY

Niedersachsen
HANNOVER

AML-BFM 2004 : Multicenter therapy-optimization trial for the treatment of Acute Myeloid Leukemias in children and adolescents - DE
KPOH Geschäftsführung Hannover
Kompetenznetz Pädiatrische Onkologie und Hämatologie

GERMANY

Niedersachsen
HANNOVER

Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) (Phase III) - DE
Medizinische Hochschule Hannover
Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation

GERMANY

Nordrhein-Westfalen
ESSEN

AML-BFM 2004 : Multicenter therapy-optimization trial for the treatment of Acute Myeloid Leukemias in children and adolescents - DE
Universitätsklinikum Essen
Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie

GERMANY

Nordrhein-Westfalen
LEVERKUSEN

CP4055-205: A Phase II Study of Elacytarabine (CP-4055) plus Idarubicin as second course remission-induction therapy in patients with Acute Myeloid Leukaemia (AML) - DE
Klinikum Leverkusen
Medizinische Klinik 3 - Onkologie, Hämatologie, Palliativmedizin, Spezielle Schmerztherapie

GERMANY

Sachsen
DRESDEN

Gentuzumab ozogamicin before allogeneic stem cell transplantation in patients with relapsed CD33+ Acute Myeloid Leukemia (Phase I-II) - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANY

Sachsen
DRESDEN

TUD-LENAMA-022: Lenalidomide maintenance therapy in patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukaemia (AML) - Phase II study - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANY

Sachsen
DRESDEN

TUD-RELAZA-008: Treatment of the haematological relapse in patients with AML and MDS following allogenic Stem Cell Transplantation with 5-Azacitidine (Vidaza®) (Phase III) - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANY

Thüringen
JENA

Phase II study of Cladribine, high-dose Cytarabine and Idarubicin in patients with relapsed acute myeloid leukemia - DE
Universitätsklinikum Jena
Klinik für Innere Medizin II - Abteilung Hämatologie und Internistische Onkologie

ITALY

FRIULI VENEZIA GIULIA
UDINE

NETHERLANDS

Gelderland
NIJMEGEN

SPAIN

Cataluña
BARCELONA

SPAIN

Cataluña
BARCELONA

SPAIN

Comunidad Valenciana
VALENCIA

APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) (Phase IV) (completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia

SPAIN

Comunidad Valenciana
VALENCIA

SPAIN

Madrid
MADRID

SPAIN

Madrid
MADRID

SPAIN

Madrid
MADRID

APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) (Phase IV) (completed)
Hospital Universitario 12 de Octubre
Servicio de Hematología y Hemoterapia

SPAIN

Madrid
MADRID

PETHEMA-LAM99: Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years (Phase IV) (terminated)
Hospital Universitario Ramón y Cajal
Servicio de Hematología y Hemoterapia

SPAIN

Navarra
PAMPLONA

UNITED KINGDOM

South Glamorgan
CARDIFF

Ongoing trial
AML 16: A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (PhaseII/III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

UNITED KINGDOM

South Glamorgan
CARDIFF

Recruiting trial
Ongoing trial
AML 17: Randomised, controlled, open label, multi-arm trial looking at treatment for acute promyelocytic leukaemia (Phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

UNITED KINGDOM

South Glamorgan
CARDIFF

AML 15: Medical research council working parties on leukaemia in adults and children. Acute myeloid leukaemia trial 15 (Phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

UNITED KINGDOM

South Glamorgan
CARDIFF

AML-HR: Protocol for patients with high risk (resistant, refractory, relapsed or adverse cytogenetic) AML (Phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

UNITED KINGDOM

Greater Manchester
NOT YET IDENTIFIED - UK

Multinational clinical trial(s)

UNITED STATES

New Jersey
RARITAN